Scientists from the University of Bristol developed a new synthetic glucose binding molecule platform, which will act as glucose-responsive insulin that will renovate the treatment of diabetes.
The team from the University’s School of Chemistry, led by Professor Anthony Davis, in collaboration with Ziylo company created a unique technology platform that would act as a key component to enable the next generation of insulin to regulate in order to glucose levels in the blood.
According to the World Health Organization estimation, over 382 million people worldwide, including 4.05 million people in the UK, have diabetes—a metabolic disorder affecting blood sugar levels. People suffering with Type 1 diabetes and Type 2 diabetes need to take insulin, either by injection or a pump, to control their blood glucose levels.
The researchers designed the innovative technology that will increase the metabolic rate of people suffering from the risk of hypoglycemia, dangerously low blood sugar level. The research work was published in the journal Nature Chemistry, titled: “A biomimetic receptor for glucose” on November 12, 2018.
Professor Davis, who has been at the forefront of research into synthetic sugar receptors for the last 20 years, said: “For many years we have been trying to design a molecule which binds glucose strongly and selectively in its natural environment (water).
The new molecule deigned by the researchers binds glucose hundred times more strongly than those previously created molecules did. It is much smaller than the natural molecules that binds glucose but is capable to perfectly select its target site and work much the same.